Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients

MLA

Gui-Qi Zhu, et al. “Development and Validation of a New Tumor-Based Gene Signature Predicting Prognosis of HBV/HCV-Included Resected Hepatocellular Carcinoma Patients.” Journal of Translational Medicine, vol. 17, no. 1, June 2019, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s12967-019-1946-8.

APA

Gui-Qi Zhu, Yi Yang, Er-Bao Chen, Biao Wang, Kun Xiao, Shi-Ming Shi, Zheng-Jun Zhou, Shao-Lai Zhou, Zheng Wang, Ying-Hong Shi, Jia Fan, Jian Zhou, Tian-Shu Liu, & Zhi Dai. (2019). Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. Journal of Translational Medicine, 17(1), 1–13. https://doi.org/10.1186/s12967-019-1946-8

Chicago

Gui-Qi Zhu, Yi Yang, Er-Bao Chen, Biao Wang, Kun Xiao, Shi-Ming Shi, Zheng-Jun Zhou, et al. 2019. “Development and Validation of a New Tumor-Based Gene Signature Predicting Prognosis of HBV/HCV-Included Resected Hepatocellular Carcinoma Patients.” Journal of Translational Medicine 17 (1): 1–13. doi:10.1186/s12967-019-1946-8.